Condition: Multiple Myeloma · Sponsor: University Hospital, Lille
The primary hypothesis of this study is that teclistamab SC in combination with daratumumab SC or lenalidomide will be safe and induce a high rate of VGPR or better in newly diagnosed multiple myeloma patients This is an open-label, multicenter, non-comparative, 2-cohort, 2-stage with interruption of enrollment for an efficacy and safety interim analysis, interventional Phase 2 study evaluating the efficacy and safety of a combination with Tec-Dara (Cohort A) or Tec-Len (Cohort B) in patients with newly diagnosed multiple myeloma who are not eligible for SCT.
This description comes directly from the study's public registry record.
Salomon MANIER, MD · 0320445962 · salomon.manier@chru-lille.fr
Always discuss trial participation with your own doctor first.
| Chu Amiens - Hopital Sud | Amiens, France | Recruiting |
| Chru Angers | Angers, France | Recruiting |
| Ch D'Avignon | Avignon, France | Active Not Recruiting |
| Centre Hospitalier de La Cote Basque | Bayonne, France | Recruiting |
| Chu de Besancon | Besançon, France | Recruiting |
| Aphp Hopital Avicenne | Bobigny, France | Not Yet Recruiting |
| Chu de Caen | Caen, France | Recruiting |
| Chu Dijon Bourgogne | Dijon, France | Recruiting |
| Ch de Dunkerque | Dunkirk, France | Active Not Recruiting |
| Chu de Grenoble | La Tronche, France | Recruiting |
| Centre Hospitalier de Versailles | Le Chesnay, France | Recruiting |
| Chu de Lille, Hopital Claude Huriez | Lille, France | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05572229